Walberg & Cie. advises deep tech start-up Neuramancer AI Solutions GmbH on financing round

Munich, March 12, 2026 – Neuramancer AI Solutions GmbH („Neuramancer“), a Bavarian deep tech start-up in the field of IT forensics, has completed a financing round to expand its AI-based platform for detecting deepfakes and AI manipulation in images and videos and to scale it internationally. Investors include Vanagon Ventures, Bayern Kapital, ZOHO.VC and Lightfield Equity, among others.

Neuramancer offers multi-stage forensic analysis software that examines image and video files for statistical artifacts and “fingerprints” of generative AI, enabling reliable statements about authenticity even with heavily compressed or partially manipulated material. The solution is already being used by media companies and businesses in the insurance industry to detect manipulated content, fake news, and fraud-related damage at an early stage and to integrate it seamlessly into existing workflows via API interfaces.

The new funds will primarily be used to further expand deepfake detection models for images, video, and, in the future, audio; to develop the media analysis platform; and to scale up in regulated industries such as media and insurance. Neuramancer also plans to strengthen its development and sales team and enter into additional strategic partnerships with industrial and technology companies in Germany and Europe.

With its deepfake detection technology, Neuramancer addresses a highly topical and socially relevant issue: the integrity of digital images and videos in the media, politics, and business. The investors' participation gives the company the necessary clout to establish its forensic AI solution internationally from its base in Bavaria.

Walberg & Cie. provided Neuramancer with comprehensive corporate and tax law advice on structuring and implementing the financing round. The focus was on a growth-oriented investment structure, the establishment of hurdle shares as a targeted investment instrument, and the tailored integration of investors.

Further information about Neuramancer: www.neuramancer.de